TickerFacts.

DBV Technologies S.A. (DBVT): Net Income

Annual figures by period end, from SEC filings.

Restated years: each year's figure is from the latest filing that reports it. The company later restated the years ended 2022-12-31, 2024-12-31 (for example after a spin-off or a discontinued operation), while the year before each was last reported on the old basis. Changes across those points are marked n/c (not comparable), and growth rates are not computed across them.

-$146.95M
Year ended 2025-12-31
$96.27M2019-12-31: -$172.01M2020-12-31: -$159.56M2021-12-31: -$97.81M2022-12-31: $96.27M2023-12-31: $72.71M2024-12-31: -$113.92M2025-12-31: -$146.95M-$146.95M
2019-12-31 Net Income (USD) 2025-12-31
Period endedNet IncomeChange YoYSource filing
2025-12-31-$146.95Mn/m2026-03-26, From 2025-01-01
2024-12-31-$113.92Mn/c2026-03-26, From 2024-01-01
2023-12-31$72.71M-24.5%2025-04-28, From 2023-01-01
2022-12-31$96.27Mn/c2025-04-28, From 2022-01-01
2021-12-31-$97.81Mn/m2023-03-02, From 2021-01-01
2020-12-31-$159.56Mn/m2022-03-09, From 2020-01-01
2019-12-31-$172.01Mn/a2021-03-17, From 2019-01-01

Net Income at similar companies

Companies with the same SEC industry code (Biological Products, (No Diagnostic Substances)), reporting in the same currency, closest in revenue. Each shows its own latest fiscal year, so period ends differ.

CompanyYear endedNet IncomeChange YoY
DBV Technologies S.A. (DBVT)2025-12-31-$146.95Mn/m
Zeo ScientifiX, Inc. (ZEOX)2025-10-31-$5.52Mn/m
Fate Therapeutics Inc (FATE)2025-12-31-$136.31Mn/m
Prime Medicine, Inc. (PRME)2025-12-31-$201.14Mn/m
Ocugen, Inc. (OCGN)2025-12-31-$67.85Mn/m
CG Oncology, Inc. (CGON)2025-12-31-$161.00Mn/m
CRISPR Therapeutics AG (CRSP)2025-12-31-$581.60Mn/m
Surrozen, Inc. (SRZN)2025-12-31-$242.03Mn/m
Curis Inc (CRIS)2025-12-31-$7.58Mn/m

Compare DBVT, ZEOX, FATE, PRME side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗